Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.29. Hemispherx BioPharma shares last traded at $0.26, with a volume of 267,240 shares traded.
Hemispherx BioPharma Stock Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Articles
- Five stocks we like better than Hemispherx BioPharma
- The 3 Best Fintech Stocks to Buy Now
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- How to Calculate Inflation Rate
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
